Please login to the form below

Not currently logged in
Email:
Password:

Synairgen

This page shows the latest Synairgen news and features for those working in and with pharma, biotech and healthcare.

AZ severe asthma drug benralizumab backed by CHMP

AZ severe asthma drug benralizumab backed by CHMP

Last year AZ's respiratory pipeline suffered another setback after the company halted a phase IIa trial of a Synairgen-partnered inhaled interferon beta formulation (AZD9412) for asthma, deciding it was

Latest news

  • Setback for AZ as tralokinumab flunks asthma trial Setback for AZ as tralokinumab flunks asthma trial

    Last year AZ's respiratory pipeline suffered another setback after the company halted a phase IIa trial of a Synairgen-partnered inhaled interferon beta formulation (AZD9412) for asthma, deciding it was

  • AZ trial adds to pessimism about anti-IL-13 asthma drugs AZ trial adds to pessimism about anti-IL-13 asthma drugs

    Last year AZ's respiratory pipeline took a further knock when it halted a phase IIa trial of a Synairgen-partnered inhaled interferon beta formulation (AZD9412) for asthma after deciding it

  • Synairgen sinks as AZ halts trial of asthma drug Synairgen sinks as AZ halts trial of asthma drug

    Synairgen sinks as AZ halts trial of asthma drug. Results from a phase II trial of inhaled antiviral therapy set to be inconclusive. ... AZD9412 is an inhaled form of interferon beta partnered with UK company Synairgen, which saw its London Stock Exchange

  • AZ licenses asthma infection drug from Synairgen AZ licenses asthma infection drug from Synairgen

    AZ licenses asthma infection drug from Synairgen. Boosts respiratory portfolio with $232m deal. ... AstraZeneca (AZ) has added to its portfolio of respiratory drug candidates after licensing an inhaled interferon beta therapy from Synairgen which is in

  • Pharma continues to attract investors

    Synairgen raises fresh cash for asthma and pulmonary disease research. Synairgen, the drug research company, rose just over 1p to 19p following a share placing at 17p to raise £6.35m – ... The cash produced by the discounted placing is to go towards

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PharmiWeb Solutions

PharmiWeb Solutions creates, delivers and manages digital solutions for the pharmaceutical and healthcare segment. From digital marketing, to patient education...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics